MYOV has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MYOV has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Myovant Sciences's Revenue for the three months ended in Dec. 2022 was $100.2 Mil. Myovant Sciences's Total Assets for the quarter that ended in Dec. 2022 was $443.7 Mil. Therefore, Myovant Sciences's Asset Turnover for the quarter that ended in Dec. 2022 was 0.23.
Asset Turnover is linked to ROE % through Du Pont Formula. Myovant Sciences's annualized ROE % for the quarter that ended in Dec. 2022 was 43.03%. It is also linked to ROA % through Du Pont Formula. Myovant Sciences's annualized ROA % for the quarter that ended in Dec. 2022 was -51.95%.
The historical data trend for Myovant Sciences's Asset Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Myovant Sciences Annual Data | ||||||||||||||||
Trend | Mar16 | Mar17 | Mar18 | Mar19 | Mar20 | Mar21 | Mar22 | |||||||||
Asset Turnover | Get a 7-Day Free Trial | - | - | - | 0.14 | 0.37 |
Myovant Sciences Quarterly Data | ||||||||||||||||||||
Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | |
Asset Turnover | Get a 7-Day Free Trial | 0.09 | 0.10 | 0.24 | 0.22 | 0.23 |
For the Biotechnology subindustry, Myovant Sciences's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Myovant Sciences's Asset Turnover distribution charts can be found below:
* The bar in red indicates where Myovant Sciences's Asset Turnover falls into.
Asset Turnover measures how quickly a company turns over its asset through sales.
Myovant Sciences's Asset Turnover for the fiscal year that ended in Mar. 2022 is calculated as
Asset Turnover | ||||||
= | Revenue | / | Average Total Assets | |||
= | Revenue (A: Mar. 2022 ) | / | ( (Total Assets (A: Mar. 2021 ) | + | Total Assets (A: Mar. 2022 )) | / count ) |
= | 230.972 | / | ( (725.027 | + | 520.011) | / 2 ) |
= | 230.972 | / | 622.519 | |||
= | 0.37 |
Myovant Sciences's Asset Turnover for the quarter that ended in Dec. 2022 is calculated as
Asset Turnover | ||||||
= | Revenue | / | Average Total Assets | |||
= | Revenue (Q: Dec. 2022 ) | / | ( (Total Assets (Q: Sep. 2022 ) | + | Total Assets (Q: Dec. 2022 )) | / count ) |
= | 100.229 | / | ( (483.974 | + | 403.521) | / 2 ) |
= | 100.229 | / | 443.7475 | |||
= | 0.23 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.
Myovant Sciences (NYSE:MYOV) Asset Turnover Explanation
Asset Turnover is linked to ROE % through Du Pont Formula.
Myovant Sciences's annulized ROE % for the quarter that ended in Dec. 2022 is
ROE %** | (Q: Dec. 2022 ) | ||||
= | Net Income | / | Total Stockholders Equity | ||
= | -230.508 | / | -535.696 | ||
= | (Net Income / Revenue) | * | (Revenue / Total Assets) | * | (Total Assets / Total Stockholders Equity) |
= | (-230.508 / 400.916) | * | (400.916 / 443.7475) | * | (443.7475/ -535.696) |
= | Net Margin % | * | Asset Turnover | * | Equity Multiplier |
= | -57.5 % | * | 0.9035 | * | -0.8284 |
= | ROA % | * | Equity Multiplier | ||
= | -51.95 % | * | -0.8284 | ||
= | 43.03 % |
Note: The Net Income data used here is four times the quarterly (Dec. 2022) net income data. The Revenue data used here is four times the quarterly (Dec. 2022) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.
It is also linked to ROA % through Du Pont Formula:
Myovant Sciences's annulized ROA % for the quarter that ended in Dec. 2022 is
ROA % | (Q: Dec. 2022 ) | ||
= | Net Income | / | Total Assets |
= | -230.508 | / | 443.7475 |
= | (Net Income / Revenue) | * | (Revenue / Total Assets) |
= | (-230.508 / 400.916) | * | (400.916 / 443.7475) |
= | Net Margin % | * | Asset Turnover |
= | -57.5 % | * | 0.9035 |
= | -51.95 % |
Note: The Net Income data used here is four times the quarterly (Dec. 2022) net income data. The Revenue data used here is four times the quarterly (Dec. 2022) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.
Thank you for viewing the detailed overview of Myovant Sciences's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.
Sumitomo Chemical Co., Ltd. | 10 percent owner | 7-1, NIHONBASHI 2-CHOME, CHUO-KU, TOKYO M0 103-6020 |
Lauren Merendino | officer: Chief Commercial Officer | C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005 |
David C Marek | director, officer: Principal Executive Officer | C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011 |
Matthew Lang | officer: General Counsel & Corp. Secy. | C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005 |
Ferreira Juan Camilo Arjona | officer: Chief Medical Officer | C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005 |
Uneek Mehra | officer: Principal Financial Officer | C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005 |
Shigeyuki Nishinaka | director | 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617 |
Nancy Valente | director | C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005 |
Terrie Curran | director | C/O MYOVANT SCIENCES INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018 |
Frank Karbe | officer: Principal Fin'l & Accounting | C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005 |
Kim Sablich | officer: Chief Commercial Officer | C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, BRISBANE CA 94005 |
Hiroshi Nomura | director | C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, BRISBANE CA 94005 |
Sumitovant Biopharma Ltd. | 10 percent owner | C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018 |
Dainippon Sumitomo Pharma Co Ltd | 10 percent owner | 6-8 DOSHOMACHI 2-CHOME, CHUO-KU, OSAKA M0 541-0045 |
Adele M. Gulfo | director | ONE NEENAH CENTER, 4TH FLOOR, P.O. BOX 669, NEENAH WI 54957 |
From GuruFocus
By Marketwired • 09-26-2023
By Value_Insider Value_Insider • 11-20-2022
By Value_Insider Value_Insider • 10-14-2022
By PRNewswire PRNewswire • 01-12-2023
By GlobeNewswire GlobeNewswire • 10-24-2022
By Value_Insider Value_Insider • 10-18-2022
By PRNewswire PRNewswire • 10-25-2022
By Value_Insider Value_Insider • 11-16-2022
By Business Wire Business Wire • 10-26-2022
By PRNewswire PRNewswire • 07-15-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.